
Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity.
about 7 years ago
Biosimilars: Some Call for ‘Cautious Optimism’about 7 years ago
Biosimilars Need Access and Cost Examinationsabout 7 years ago
The Latest Autoimmune Disease Treatment Advancesabout 7 years ago
Unique Offerings Increasing Revenueabout 7 years ago
The Growing Problem of Pharmacy Desertsabout 7 years ago
What is a Pharmacy Desert?about 7 years ago
Patient Services are Crucial to the Economics of Pharmacyabout 7 years ago
New Video Marketing Toolsabout 7 years ago
Antimicrobial Stewardship: Protecting Global Health





